Trump administration cuts reach FDA employees in food safety,Tobacco centers are affected

Feb.21.2025
Trump administration cuts reach FDA employees in food safety,Tobacco centers are affected
New FDA hires hit with layoffs as Trump administration cuts federal workforce, food, medical device safety inspections employees to be fired.

According to a report from AP News on February 17, the Trump administration's cuts to the federal workforce have spread to the FDA over the weekend, leading to the dismissal of newly hired employees responsible for food ingredient and safety inspections.


According to three anonymous FDA employees, probationary employees at the FDA received notice on Saturday evening (the 15th) that their positions were being eliminated. The layoffs primarily affected employees in the Center for Food, Medical Devices, and Tobacco, and may also involve staff working on e-cigarette products, although it is not yet clear if drug review staff are included.


Last Friday (14th), the Department of Health and Human Services in the United States announced plans to lay off 5200 probationary employees within its various agencies, including the National Institutes of Health, the Centers for Disease Control and Prevention, and the FDA. The FDA, headquartered in the suburbs of Maryland near Washington, has nearly 20,000 employees.


The newly-appointed Secretary of Health, Robert Kennedy Jr., has long targeted the FDA, accusing the agency of failing to approve unproven therapies such as psychedelics, stem cell therapy, and chelation therapy, which he believes poses a "war" on public health.


Little Kennedy also called for the removal of thousands of chemicals and colors from American food. However, FDA employees familiar with the layoffs have revealed that the layoffs also involve employees responsible for reviewing the safety of new food additives and ingredients.


The spokesperson for the Ministry of Health did not respond to requests for comment on Sunday afternoon (16th). Nearly half of the FDA's $6.9 billion budget comes from fees paid by its regulated entities, including drug and medical device manufacturers, which allows the FDA to quickly hire scientists to review products, therefore layoffs will not decrease government spending.


A former FDA official has warned that laying off new employees could backfire, as these employees are typically younger and equipped with the latest technological skills. The FDA has long faced difficulties in recruiting and retaining staff due to private companies offering better salaries.


Former FDA Center for Tobacco Products director Mitch Zeller said the layoffs are a way of "hitting and weakening the morale of federal employees.


Their measures will undermine the ability to attract and retain talent.


In recent years, with the rise of the COVID-19 pandemic and a wave of resignations, the FDA workforce is under pressure with many of its current inspectors being new hires. It is unclear if these employees have been excluded. FDA inspectors are responsible for overseeing thousands of food, drug, tobacco, and medical device facilities globally, but according to an AP news report last year, the agency faced a backlog of inspections at approximately 2,000 facilities due to the pandemic.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BofA Upgrades Imperial Brands, Says Market Overreacted to Australia Slump
BofA Upgrades Imperial Brands, Says Market Overreacted to Australia Slump
Bank of America upgraded Imperial Brands to “buy” from “neutral,” saying investors have overreacted to the tobacco group’s Australian business downturn and that the share-price pullback has created a more attractive entry point.
Jul.16
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
British American Tobacco’s New Category revenue rose 18% at constant rates in the first half of 2026. Nicotine-pouch brand Velo expanded rapidly, while Vuse recovered as U.S. enforcement against illicit e-vapor products strengthened. Heated-tobacco platform glo remained under pressure, and cigarettes continued to provide most of the group’s profit and cash. Compared with PMI and JT, BAT has more routes to growth—but also greater regulatory, investment and execution risks across its broader portfolio.
BAT
Jul.30
2Firsts Interview | InterTabac 2026 Adapts to a More Complex Tobacco and Nicotine Market
2Firsts Interview | InterTabac 2026 Adapts to a More Complex Tobacco and Nicotine Market
As InterTabac 2026 approaches, Sabine Loos, Managing Director of Westfalenhallen Unternehmensgruppe, tells 2Firsts that global tobacco trade fairs are evolving beyond product display. With new nicotine categories, shifting regulation and more complex supply chains reshaping the industry, InterTabac is positioning itself as a platform for market insight, regulatory discussion and global business connection.
Special Report
Jul.02
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
PMI Q2 Revenue Rises 10.4% as IQOS and VEEV Expand, U.S. ZYN Growth Slows
Philip Morris International’s second-quarter net revenues rose 10.4% to a record $11.19 billion, as heated tobacco and e-vapor expanded across international markets. IQOS remained the main smoke-free growth engine, while VEEV shipments jumped 55.1%. In the United States, however, ZYN shipments increased just 1.8% and consumer offtake was broadly flat to slightly higher. Cigarette volumes also rose, showing that PMI’s transformation is advancing, but growth is becoming increasingly uneven across categories and markets.
PMI
Jul.22
BP, Marathon and Valero Warn U.S. Gas-Station Stores: Illegal Vape Sales Could Bring Heavy Fines and Card-Processing Limits
BP, Marathon and Valero Warn U.S. Gas-Station Stores: Illegal Vape Sales Could Bring Heavy Fines and Card-Processing Limits
Fiserv and service station operators including BP, Marathon Petroleum and Valero have warned U.S. partners and gas-station convenience-store owners that selling illegal vapes could lead to heavy fines, breach brand agreements and even put stores’ card-processing access at risk, according to Reuters.
Regulations
Jul.07 by 2Firsts Perspectives
Product | IVG Pro 15K Enters European Retail Channels, Expanding High-Capacity Pod System Segment
Product | IVG Pro 15K Enters European Retail Channels, Expanding High-Capacity Pod System Segment
UK vape brand IVG has introduced the IVG Pro 15K, a high-capacity pod system combining a 2ml prefilled pod with a 10ml refill container to deliver up to 15,000 puffs. Unlike conventional high-puff disposable vapes, the IVG Pro 15K adopts a reusable device structure, reflecting a broader shift in the European vape market toward longer-use-cycle products and reusable hardware ecosystems.
Jul.14